EFFECTS OF SEMAGLUTIDE ON CHRONIC KIDNEY DISEASE OUTCOMES: A POST HOC POOLED ANALYSIS FROM THE SUSTAIN 6 AND PIONEER 6 TRIALS

被引：0
|
作者：
Tuttle, Katherine
Cherney, David
Hadjadj, Samy
Idorn, Thomas
Mosenzon, Ofri
Perkovic, Vlado
Rasmussen, Soren
Wolthers, Benjamin
Bain, Stephen C.
机构：
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2020年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
MO051
引用
收藏
页码：152 / 152
页数：1
相关论文
共 50 条
  • [31] Semaglutide reduces hsCRP levels across different treatment settings: post hoc analyses of SUSTAIN and PIONEER trials
    Mosenzon, O.
    Capehorn, M.
    De Remigis, A.
    Rasmussen, S.
    Weimers, P.
    Rosenstock, J.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 95 - 96
  • [32] Semaglutide reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes: Post hoc analyses of the SUSTAIN 6 and PIONEER 6 trials
    Verma, Subodh
    David, Jens-Peter
    Leiter, Lawrence A.
    Michelsen, Marie Mide
    Rasmussen, Soren
    Bhatt, Deepak L.
    DIABETES OBESITY & METABOLISM, 2023, 25 (08): : 2388 - 2392
  • [33] Estimating cardiovascular disease-free life-years with the addition of semaglutide in people with type 2 diabetes using pooled data from SUSTAIN 6 and PIONEER 6
    Westerink, J.
    Matthiessen, K. Sommer
    Nuhoho, S.
    Fainberg, U.
    Wolden, M. Lyng
    Visseren, F.
    Sattar, N.
    EUROPEAN HEART JOURNAL, 2020, 41 : 3069 - 3069
  • [34] EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES - A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS
    Perkovic, Vlado
    Bain, Stephen
    Bakris, George
    Buse, John
    Idorn, Thomas
    Mahaffey, Kenneth
    Marso, Steven
    Nauck, Michael
    Pratley, Richard
    Rasmussen, Soren
    Rossing, Peter
    Tornoe, Karen
    Zinman, Bernard
    Mann, Johannes
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 : 338 - 338
  • [35] The effect of semaglutide once weekly on MACE and blood pressure by race and ethnicity: SUSTAIN 6 post hoc analysis
    Desouza, C.
    Bain, S. C.
    Gondolf, T.
    Hansen, T.
    Holst, I.
    Rea, R. R.
    Seufert, J.
    EUROPEAN HEART JOURNAL, 2019, 40 : 3876 - 3876
  • [36] EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) - A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER
    Perkovic, Vlado
    Bain, Stephen
    Bakris, George
    Buse, John
    Idorn, Thomas
    Mahaffey, Kenneth
    Marso, Steven
    Nauck, Michael
    Pratley, Richard
    Rasmussen, Soren
    Rossing, Peter
    Tornoe, Karen
    Zinman, Bernard
    Mann, Johannes
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 : 205 - U715
  • [37] Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6
    Nauck, Michael A.
    Quast, Daniel R.
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [38] Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials
    DeSouza, Cyrus
    Cariou, Bertrand
    Garg, Satish
    Lausvig, Nanna
    Navarria, Andrea
    Fonseca, Vivian
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (02): : 543 - 556
  • [39] Estimating CVD-free life-years with the addition of semaglutide in people with type 2 diabetes using pooled data from SUSTAIN 6 and PIONEER 6
    Westerink, J.
    Matthiessen, K. Sommer
    Nuhoho, S.
    Fainberg, U.
    Wolden, M. Lyng
    Visseren, F.
    Sattar, N.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S51 - S52
  • [40] Effects of once-weekly semaglutide on major adverse cardiovascular events in patients with type 2 diabetes and polyvascular disease: a post hoc analysis of the SUSTAIN 6 trial
    Kobo, O.
    Cavender, M. A.
    Gylvin, S. Hinsch
    Kuhlman, A. B.
    Rasmussen, S.
    Verma, S.
    EUROPEAN HEART JOURNAL, 2023, 44
12345